From Entresto To Ozempic: This Week In Generics Litigation
By Hannah Albarazi · September 30, 2025, 6:26 PM EDT
Friction between brand-name and generic-drug makers escalated this past week, with the D.C. Circuit rejecting Novartis' challenge to a generic for heart medication Entresto, Pfizer looking to enforce a patent over its anti-inflammatory drug...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login